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Objectives: to survey the prevalence of human papillomavirus, associated risk factors and 
genotype distribution in women who were referred to cervical cancer screening when attended 
in a Family Health Program. Method: we conducted a cross-sectional survey, investigating 
351 women. Polymerase chain reaction for DNA amplification and restriction fragment length 
polymorphism analysis were used to detect and typify the papillomavirus. Results: virus infection 
was detected in 8.8% of the samples. Among the 21 different genotypes identified in this study, 
14 were high risk for cervical cancer, and the type 16 was the most prevalent type. The infection 
was associated with women who had non-stable sexual partners. Low risk types were associated 
with younger women, while the high risk group was linked to altered cytology. Conclusion: in this 
sample attended a Family Health Program, we found a low rate of papillomavirus infection. Virus 
frequency was associated to sexual behavior. However, the broad range of genotypes detected 
deserves attention regarding the vaccine coverage, which includes only HPV prevalent types.
Descriptors: Papillomavirus Infections; Genotype; Preventive Health Services.
Human papillomavirus detection in cervical scrapes from women 
attended in the Family Health Program1
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Introduction
The dynamic of human papillomavirus infection 
in the female genital tract comprises a broad range of 
events. They include latent, transient, persistent and 
benign warts, low and high grade squamous lesions and 
cervical cancer(1). Despite the existence of more than 
40 genital and anogenital types, progression to cervical 
cancer is associated with approximately 15 high risk 
types(2). Because the progression from normal tissue 
to malignant disease is continuous and can be delayed 
until several years after infection, intervening in the 
early steps of this process will prevent the development 
of cancer.
The Papanicolau (Pap) cytological test, a low 
cost exam, allows for the screening, detection and 
management of neoplastic abnormalities, preventing 
women from developing malignant disease. The 
sensitivity of this test is estimated to be approximately 
75% (due to false negatives or false positives), but the 
use of appropriate screening highly reduces the cervical 
cancer rates in a covered population(3).
The knowledge that HPV infection is essential 
for cervical cancer development has led to the 
implementation of additional strategies in cervical 
cancer prevention programs. As an effective tool, HPV 
DNA testing focusing on high-risk types has been 
considered, which is more sensitive than Pap screening, 
although it has lower specificity than cytology(4). To 
improve the accuracy of early detection, triage with 
HPV DNA tests plus cytology will aid in the early 
diagnosis of HPV infection, thus protecting women from 
developing cervical cancer(5). Besides, data about HPV 
genital infection reveal important aspects of the virus’ 
geographic distribution, which differs across regions and 
other demographic factors. In Brazil, this test is solely 
offered through the private healthcare network because 
it entails higher costs and more logistic support than 
cytological screening. Hence, the knowledge of HPV 
infection among women attended public health services 
has been obtained through regional studies that show 
the virus and its prevalent genotypes, as well as the 
cultural factors that act in particular regions of the 
country. In the HPV vaccine era, such information is 
useful for vaccination strategies.
According to a Ministry of Health report, the 
estimated cervical cancer incidence in Brazil for 2012 
was 17,540 new cases. Of these, 2,030 cases occurred 
in the state of Rio de Janeiro(6). Brazilian health policies 
recommend the cytology-based Papanicolaou test for 
cervical cancer control at periodic intervals for women 
aged 25-59 years or after their sexual debut(7). Because 
the impact of HPV vaccines in cervical cancer is still not 
entirely known, they are approved for women attending 
private clinics, but they are not available through the 
public health system.
Family Health programs that include cervical cancer 
prevention have been implemented in several cities 
from the State of Rio de Janeiro. These programs offer 
preventive screening to women living in these cities at 
regular intervals. In a previous study, we analyzed 351 
women referred to a Family Health Program from Rio 
de Janeiro state(8). Most of these women (96.3%) had 
normal or inflammatory cytology. In order to provide 
additional data to ratify the cervical cancer control 
strategies, we surveyed the HPV prevalence in this 
people in the light of the routine Pap smear screening. 
We have also investigated the possible co-factors for 
the infection. In view of large number of HPV types, we 
determined the frequency of genotypes distribution and 
grouped the identified types by species.
Method
We conducted a cross-sectional survey, 
investigating 351 women who were referred to the 
Family Health Program from Niterói city, State of Rio de 
Janeiro, between March 2009 and November 2010. The 
women included in this work had at least one sexual 
partner in their lifetime and were registered in the 
Family Health Program. Pregnancy and hysterectomy 
were excluding factors. No women were vaccinated 
against HPV. Demographic data were obtained through 
a structured household questionnaire. The Ethics 
Committee of the College of Medicine of the University 
provided ethical clearance for the protocol and 
informed consent (CEP CMM/HUAP 052/2010, CAAE 
0037.0.258.000-10). This sampling method and the 
profile of this population has already been described(8). 
Briefly, they were 17 to 79 years old. Most of them 
gained a monthly family income superior to U$600 
and 57.3% had attended only elementary school or 
reported illiterate conditions. Non white people were 
the most prevalent ethnic group. Most of the women 
maintained a stable sexual partner and had up to three 
sexual partners in the lifetime, with one partner during 
the last three months. Nearly half began their sexual 
life before the age of 17 years.
Women were submitted to routine gynecological 
examination. They attended the service upon their 
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own initiative with a previous appointment, or were 
encouraged by a health care professional to attend 
their screening. Cervical samples were collected after 
clinical examination. Two cervical specimens were 
collected from each participant using a cervical brush. 
The first sample was spread onto a glass slide to be 
processed for Papanicolau staining. The remaining 
specimen, containing ectocervical and endocervical 
cells, were placed in Tris EDTA buffer (10 mM Tris pH 
7.4, 1 mM EDTA) and stored at -20ºC until HPV testing 
was performed.
According to the Bethesda nomenclature, cervical 
smears were classified as normal/inflammatory, atypical 
squamous cells of undetermined significance (ASCUS), 
low grade squamous intraepithelial lesions (LSIL) or 
high grade squamous intraepithelial lesions (HSIL)(9).
DNA was extracted from the cervical samples 
with phenol-chloroform-isoamyl alcohol. MY09/11 
consensus primers were used to detect generic HPV 
DNA. These primers are universal and detect a large 
number of epithelial and mucosal papillomavirus. HPV 
typing was performed by restriction fragment length 
polymorphism analysis (RFLP) following polymerase 
chain reaction (PCR) DNA amplification. The resultant 
450 base pair PCR products were digested by six 
restriction enzymes (BamHI, DdeI, HaeIII, HinfI, PstI, 
RsaI; Invitrogen, São Paulo, Brazil). The RFLP pattern of 
each sample was analyzed by agar gel electrophoresis 
under ultraviolet light and compared with the RFLP 
patterns for mucosal HPV(10). HPV types were clustered 
according to biological and philogenetic criteria(11). 
Specimens were classified as high risk if they had at 
least one high risk HPV type, and low risk if they had 
only low risk HPV types.
A data bank was generated and analyzed using 
the Epi Info statistical package (version 3.5.1, 
2008, CDC). Statistical analyses were performed for 
laboratory diagnosis, risk and demographic factors for 
HPV infection. The association between epidemiological 
variables and HPV was examined by analysis with 
odds ratios and p values. To investigate independent 
associations, variables with p≤0.1 were included in the 
multiple logistic regression analyses. p values equal or 
lower than 0.05 were considered statistically significant.
Results
Demographic and behavior data have already been 
described in a previous paper(8).
Women aged 14 to 79 years old, mean age 38.43 
year, standard deviation 14.26. We found 282 women 
above 25 years (64.95%). Most of them gained a 
monthly family income superior to U$600 and 57.3% 
had attended only elementary school or reported 
illiterate conditions. Non white people were the most 
prevalent ethnic group. Most of the women maintained 
a stable sexual partner and had up to three lifetime 
sexual partners, with one partner during the last 
three months. Nearly half began their sexual life up 
to the age of 17 years. Sixty-one percent and 55.0% 
of the women had never used cigarettes and alcohol. 
Preservatives were not used by 67.2% of women and 
contraceptive methods by 83.5%. Parity until two 
children was reported by 69.2% of the women, of whom 
32.8% related abortion episodes. Most of the women 
(82.3%) did not refer to any sexually transmitted 
diseases (Table 1). Among the remaining women, 
23 (6.6%) related clinical symptoms of condyloma, 
18(5.1%) candidiasis, syphilis 14 (4.0%), gonorrhea 3 
(0.9%), hepatitis B 2 (0.6%), Chlamydia 1 (0.3%), and 
genital herpes 1 (0.3%).
Most women (338) had normal cytology (96.3%), 
five had ASCUS (1.4%), three had LSIL (0.9%), one 
had HSIL 1(0.3%) and four were excluded because 
of inconclusive findings (1.1%)(8). HPV infection was 
present in 8.8% (31/351) of the samples. As expected, 
altered cytology was significantly associated with 
infection (Table 1). However, after adjusted OR, the 
result lost significance (OR 4.4, CI [0.96-20.48], 
p=0.056). Viral infection was less frequent among 
women who underwent regular Pap screening, but 
preventive exam at least once during the lifetime did 
not affect the cytological status. In spite of this, it is 
remarkable that regular Pap exams lead to a reduction 
of the virus frequency (Table 1).
Women with high and low risk types corresponded 
to 4.0% and 4.8%, respectively. High risk HPV genotypes 
were only strongly associated with cellular changes (OR 
14.77, CI [3.26-66.90], p=0.003). This association 
remained (OR 9.97, CI [2.07-47.85], p=0.004) in the 
multivariate model. In spite of this, 11 (3.3%) women 
with normal or inflammatory cytology were infected by 
high risk HPV.
Low risk types were not associated with changes 
in cytology. However, women who had not undergone 
regular screening had a greater probability of acquiring 
low risk HPV types (OR 3.94, CI [1.46-10.64], 
p=0.01).
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Variables (N=351)
HPV infection
OR (CI 95%) p valuePositive Negative
n (%) n (%)
Cytology* 0.039
ASCUS, LSIL, HSIL 3 (33.3) 6 (66.7) 5.75 (1.36-24.32)
Normal, inflammatory 27 (8.0) 311 (92.0) 1 (Ref)
Pap test 0.080
No 4 (23.5) 13 (76.5) 3.49 (1.06-11.47)
Yes 27 (8.1) 307 (91.9) 1 (Ref)
Pap test 0.020
Irregular intervals 11 (15.9) 58 (84.1) 2.48 (1.12-5.46)
Advised intervals 20 (7.1) 262 (92.9) 1 (Ref)
Table 1 - HPV positivity versus cytological results and Pap smear screening, Niterói, RJ, Brazil, 2009-2010
Table 2 - Demographic and lifestyle data for study participants, Niterói, RJ, Brazil, 2009-2010
*Four samples were rejected
Among the demographic variables, the univariate 
analysis revealed that an age of more than 24 years 
was a protective factor for infection (Table 2). Women 
who had the same sexual partner for more than one 
year were less exposed to HPV infection than those 
who did not have a stable sexual partner, although 
the frequency of virus infection did not depend on the 
number of sexual partners during their life or the age 
of sexual debut (Table 2).
Although not significant, a non-white ethnicity 
showed a weak trend. The other factors, including 
schooling and socioeconomic status, were not 
associated with infection in these people. It was not 
associated either with preservatives, contraceptive 
methods, abortion or number of parities. Smoking 
and alcohol consumption habits failed to demonstrate 
any association with the detection of HPV DNA 
(Table 2).
Variables (N=351)
HPV infection
OR (CI 95 %) p valuePositive Negative
n (%) n (%)
Civil status 0.001
Non-stable sexual partners 19 (61.3) 99 (30.9) 3.53 (1.65-7.56)
Living together for > 1 year 12 (38.7) 221 (69.1) 1 (Ref)
Age 0.011
15-24 years 12 (38.7) 57 (17.8) 2.94 (1.35-6.66)
25 years or older 19 (61.3) 263 (82.2) 1 (Ref)
Ethnicity 0,080
Non-white 25 (80.6) 202 (63.1) 2.43 (0.97-6.10)
White 6 (19.4) 118 (36.9) 1 (Ref)
Alcohol drinking 0.086
Yes 19 (61.3) 139 (43.4) 2.04 (0.98-4.39)
No 12 (38.7) 181 (56.6) 1 (Ref)
Number of lifetime sexual partners 0.116
>3 15 (48.4) 108 (33.8) 1.84 (0.87-3.86)
1-3 16 (51.6) 212 (66.2) 1 (Ref)
Contraceptive methods 0.411
No 3 (9.6) 55 (17.2) 0.51 (0.15-1.75)
Yes 28 (90.4) 265 (82.8) 1 (Ref)
Schooling 0.443
Illiterate 0 15 (4.07) 0.90 (0.87-0.93)
Elementary school or more 31 (100) 305 (95.3) 1 (Ref)
Smoking 0.589
Any time 14 (45.2) 123 (38.4) 1.31 (0.62-1.72)
Never 17 (54.8) 197 (61.6) 1 (Ref)
(continue...)
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Table 2 - (continuation)
Variables (N=351)
HPV infection
OR (CI 95 %) p valuePositive Negative
n (%) n (%)
Family income 0.598
≤$500.00 13 (41.9) 118 (37.1) 0.81 (0.38-1.72)
>$500.00 18 (58.1) 200 (62.9) 1 (Ref)
Parity 0.701
>3 12 (38.7) 141 (44.1) 0.80 (0.37-1.70)
≤3 19 (61.3) 179 (55.9) 1 (Ref)
First sexual experience 0,814
≤16 years 15 (50) 147 (45.9) 0.85 (0.40-1.79)
>16 years 15 (50) 173 (54.1) 1 (Ref)
Abortion 0.841
Yes 9 (32.9) 105 (32.9 1.19 (0.53-2.69)
No 22 (71.0) 214 (67.1) 1 (Ref)
Current smoking habit 0.953
Yes 14 (45.2) 123 (38.4) 0.91 (0.43-1.91)
No 17 (54.8) 197 (61.6) 1 (Ref)
Preservative use 1.00
No 24 (77.4) 245 (76.6) 1.05 (0.43- 2.53)
Yes 7(22.6) 24 (23.4) 1 (Ref)
To identify independent factors associated with HPV 
infection, we performed a multiple logistic regression 
analysis between HPV and covariates with a statistical 
significance threshold of less than 0.10. The data for 
the final model are shown in Table 3. HPV infection 
remained associated with women who had non-stable 
sexual partners. The remaining factors did not show 
significance (Table 3).
Table 3 - Adjusted OR for identifying independent 
variables in HPV infection, Niterói, RJ, Brazil, 2009-2010
Figure 1 - The prevalence of HPV by age ranges among 
participants of Family Health Program, Niterói, RJ, Brazil, 
2009-2010
Variables Adjusted OR 95% CI p value
Non-stable sexual partners 2.73 (1.23-6.05) 0.013
<25 years of age 2.17 (0.96-5.00) 0.065
Alcohol consumption 1.95 (0.89-4.24) 0.092
Non-white ethnicity 1.94 (0.75-4.99) 0.168
Although not significant, the rate of infection 
among positive cases ranged from 41.9% in ages below 
25 years to 5.9% in women older than 55 years (Figure 
1). High risk HPV infections were not age dependent in 
the dichotomous age distribution, although they were 
more frequent (p=0.09) and showed more type diversity 
between 25-35 ages, as shown in Figure 1.
Among the 21 different HPV genotypes identified in 
this study, 11 were low risk types and 10 belonged to 
the high risk group. Two infections could not be typed. 
HPV 16 was the most prevalent type (11.5% of all typed 
infections). We found four mixed HPV co-infections 
(6,16; 6,18;16,52;52,66; 61,54).
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The high risk HPV types were classified into A5, A6, 
A7 and A9 species groups, according to biological and 
phylogenetic criteria(11), and represented 47.04% of the 
individual genotypes. The classical oncogenic species A9 
was responsible for one third of the detectable infections 
and included HPV 16 infections. After clustering the 
individual genotypes by species, we verified that the low 
risk types belonged to the A3, A7, A8, A10, A13 and A15 
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species groups. These genotypes contributed to 52.92% 
of the infections.
A9 species were present in almost all age categories, 
saving the oldest women, who had no high risk infection. 
A7 species were seen only in the youngest participants.
Concerning low risk HPV types, the prevalence 
of these genotypes was affected by an age of less 
than 25 years (OR 7.14, CI [2.5-20], p<0.0001). So, 
this incidence peak corresponded to HPV infection at 
younger ages (Figure 1). A10 species, including 6 and 
11 types, was not prevalent in this group. One woman 
over 55 years old had been infected by the uncommon 
HPV type 40.
Discussion
This study was carried out to strengthen the 
knowledge about the HPV genotypes in a female 
population in the Brazilian Family Health Program. We 
investigated women who had low risk of HPV infection 
and cervical cancer development. According to our 
results, 96.3% had normal or inflammatory cytology. 
Even considering the moderate sensibility of Pap test, 
we verified that 92.9% of the women submitted to 
regular Pap test were free from detectable HPV DNA 
and 96.4% free from high risk HPV. In addition, among 
women with normal or inflammatory result, 82.6% was 
not infected with HPV. A negative test result indicates a 
very low chance of a woman to be at risk of developing 
cancer. Thus, the organized screening program has been 
successful.
The overall HPV prevalence found in our sample 
of Brazilian women (8.8%) was low in comparison with 
other similar studies(12). In a systematic review of the 
literature(13), HPV prevalence in Brazil ranged from 13.7 
to 54.3%. As the mean age of the sample was over 35 
years old and the trend of HPV prevalence was linear 
and decreased with age, this HPV rate may be explained 
by the clearance at older ages, prevalent in this sample.
Concerning determinants which affected the HPV 
positivity, a strong relationship between HPV and non-
stable sexual partners was observed and confirmed by 
regression analysis. Women who had the same sexual 
partner for more than one year were more probable to 
avoid infection. However, other lifestyle parameters, 
such as age at the first sexual experience and number 
of lifetime sexual partners, were not significant for HPV 
infection. Considering the cross-sectional characteristic 
of this study, transient infections could disguise these 
associations.
The highest frequency of HPV infection was 
present in women up to 25 years old, consistent with 
the data already described(14). HPV positivity declined 
at older ages, probably because younger women were 
more likely to harbor low risk HPV infections than older 
women, a significant result that closely relates low risk 
genotypes with transient infections. The prevalence 
of overall HPV and low risk types showed a similar 
distribution, whereas high risk types were distributed in 
a different epidemiologic profile. A less common low risk 
HPV 40 was detected in an old woman, perhaps because 
she should be naïve to such type. Low risk types were 
spread among six species through all the age groups, 
strengthening the character of transient infections. 
Compared with other similar studies in Brazil and 
worldwide, which indicate the prevalence of high risk 
HPV at young ages, our results were contrasting(15-17). 
Oncogenic HPV were solely linked to abnormal cytology, 
but this event was a consequence rather than a risk 
factor. We can interpret these data as a result of the 
persistence of high risk types in cervical cells, regardless 
of any other variable.
The large number of HPV genotypes found was 
similar to that observed in other studies performed in 
the same geographic area. In a previous survey with 
asymptomatic youngsters, we found 19 HPV types(15), 
and another related Brazilian study identified 24 
types(18). According to the Ministry of Health(7), in Brazil, 
the most common types found are 16, 31, 18, 6, 35, 58, 
33, 11, 54 and 68 in normal cytology samples; 16, 51, 
31, 18, 58, 33, 35, 39, 56 and 59 in low grade lesions; 
and 16,11, 58, 18, 31, 6, 33, 45, 66 and 35 in high 
grade lesions. Less frequent types, such as 52, 61, 81 
and 84, were found in our study; most of these types 
belong to the low risk group. This group suggests the 
transient character of these infections, which are usually 
cleared by the immune system. Otherwise, most high 
risk infections belonged to the A9 species, and among 
them, the HPV 16 genotype was dominant. Among 338 
women with normal or inflammatory cytology, 11(3.3%) 
harbored high risk HPV. High risk HPV positivity should 
indicate a need for follow-up to verify the clearance of 
virus and the non development of abnormal cells. It is 
worth mentioning that A9 species were involved in three 
out of five co-infections.
Currently, immunization against the most 
common genital HPV types is being used as the 
primary preventative measure for cervical cancer. 
Two HPV vaccines, Gardasil® (against types 6, 11, 
16 and 18) and CervarixTM (against types 16 and 18) 
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target preadolescent children. The current guidelines 
recommend immunization for those aged from 9 to 
26 years(19). It is of interest to inform that, out of 78 
young women sexually active at 25 years or less, 5 had 
at least A7 or A9 HPV genotype. On the other hand, 
natural seroconversion to HPV 16 or 18 does not protect 
against other types of same species(20). Considering the 
local occurrence of such types, women infected with 
HPV 16 or 18 will continue susceptible to HPV 31, 52, 
58 and 59.
In Brazil, the vaccination is in practice only through 
private clinics. One of the reasons why the government 
has not yet included the HPV vaccine in the national 
vaccination program is related to the few oncogenic 
types covered by the vaccines(21). The development of 
a second generation multigenic vaccine will maximize 
HPV protection.
Systematic cervical cancer screening in a public 
healthcare program with good compliance favors the 
acquisition of knowledge about the prevention of sexually 
transmitted infections. We suggest that information and 
support from basic healthcare staff could be associated 
with the low rate of HPV infection found in this study. In 
this way, nurse practitioners have played an important 
role in answering patients’ questions about HPV infection 
and prevention, regarding women’s health.
This study has several limitations. The small size 
of the sample may produce unstable findings, since 
the small number of infections can distort the analysis. 
Cross-sectional design does not permit distinctions 
between persistent and transient infections. Despite 
this, the participants were screened for genital HPV 
through molecular biological assay, complementing the 
Pap test. HPV DNA is an expensive test, only available 
in private laboratories. For us, the results provide a 
basis for studies on the HPV phylogenetic tree and 
vaccine type variants, which are being developed in 
our department. Furthermore, offering guidance to 
women about cancer prevention at the time of the 
sample collection and interviews was one of the main 
contributions of the professional staff, focusing on 
health and education.
Conclusion
We found, in this sample attended in a Family 
Health Program, a low rate of papillomavirus infection. 
However, the broad range of genotypes detected 
deserves attention regarding the vaccine coverage, 
which includes only prevalent types.
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